Company news

Tenaya Therapeutics, Inc. news in 2022

Tenaya Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

December 6, 2022

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

November 27, 2022

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

Tenaya Therapeutics Announces Closing of Public Offering

November 20, 2022

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

November 3, 2022

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

October 3, 2022

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

September 28, 2022

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

September 28, 2022

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 5, 2022

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

September 5, 2022

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 9, 2022

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

July 5, 2022

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

June 15, 2022

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

May 19, 2022

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

April 27, 2022

Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates

March 22, 2022

Tenaya Therapeutics Provides 2022 Business Updates

January 9, 2022

Decks in 2022